Studies of NF-κB, most notably haematological malignancies, demonstrate that aberrant expression of this transcription factor is associated with tumour growth, progression and resistance to chemotherapeutic agents (Baud and Karin, 2009). Here, NFKB1 is linked to neoplasm.